Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed group of drugs. Patients receiving NSAIDs often experience abdominal discomfort, and some of them develop serious gastrointestinal complications, such as ulceration, bleeding, perforation, or obstruction. Gastrointestinal side effects of NSAIDs are mostly attributed to cyclooxygenase (COX) inhibition resulting in reduction of prostaglandin in gastric mucosa. Topical irritant effects are also contributed to their systemic effect of prostaglandin inhibition. Anti-inflammatory effects of NSAIDs are mediated by COX-2 inhibition, while COX-1 inhibition is responsible for gastric prostaglandin inhibition. Management of gastrointestinal complications of NSAIDs is costly. In order to prevent or treat the gastrointestinal complications of NSAIDs, anti-ulcer drugs can be used concomitantly. Other alternative is the application or substitution of COX-2 selective inhibitors, which spare gastric mucosal prostaglandin synthesis and do not damage the gastric mucosa. Application of COX-2 selective inhibitors as a first line treatment for arthritic disorders may not be cost-effective, if patients do not have any risk factors including advanced age, history of complicating peptic ulcer, concomitant anticoagulant and corticosteroid medication. Patients with risk factors or those developing gastrointestinal complications during the course of NSAID treatment can be treated with COX-2 selective inhibitors if necessary.
Keywords: nonsteroidal anti-inflammatory drug, cyclooxygenase, prostaglandin, gastrointestinal complications
Current Pharmaceutical Design
Title: Gastrointestinal Effects of Selective and Non-Selective Non-Steroidal Anti- Inflammatory Drugs
Volume: 11 Issue: 14
Author(s): U. S. Akarca
Affiliation:
Keywords: nonsteroidal anti-inflammatory drug, cyclooxygenase, prostaglandin, gastrointestinal complications
Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed group of drugs. Patients receiving NSAIDs often experience abdominal discomfort, and some of them develop serious gastrointestinal complications, such as ulceration, bleeding, perforation, or obstruction. Gastrointestinal side effects of NSAIDs are mostly attributed to cyclooxygenase (COX) inhibition resulting in reduction of prostaglandin in gastric mucosa. Topical irritant effects are also contributed to their systemic effect of prostaglandin inhibition. Anti-inflammatory effects of NSAIDs are mediated by COX-2 inhibition, while COX-1 inhibition is responsible for gastric prostaglandin inhibition. Management of gastrointestinal complications of NSAIDs is costly. In order to prevent or treat the gastrointestinal complications of NSAIDs, anti-ulcer drugs can be used concomitantly. Other alternative is the application or substitution of COX-2 selective inhibitors, which spare gastric mucosal prostaglandin synthesis and do not damage the gastric mucosa. Application of COX-2 selective inhibitors as a first line treatment for arthritic disorders may not be cost-effective, if patients do not have any risk factors including advanced age, history of complicating peptic ulcer, concomitant anticoagulant and corticosteroid medication. Patients with risk factors or those developing gastrointestinal complications during the course of NSAID treatment can be treated with COX-2 selective inhibitors if necessary.
Export Options
About this article
Cite this article as:
Akarca S. U., Gastrointestinal Effects of Selective and Non-Selective Non-Steroidal Anti- Inflammatory Drugs, Current Pharmaceutical Design 2005; 11 (14) . https://dx.doi.org/10.2174/1381612053764904
DOI https://dx.doi.org/10.2174/1381612053764904 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches
Protein & Peptide Letters VEGF, Angiopoietin-1 and -2 in Bronchial Asthma: New Molecular Targets in Airway Angiogenesis and Microvascular Remodeling
Recent Patents on Inflammation & Allergy Drug Discovery Systemic Autoimmune Manifestations: When Should Underlying Thyroid Autoimmunity be Considered?
Current Rheumatology Reviews Preface
Current Pharmaceutical Design mTOR Signaling and Metabolic Regulation of T Cells: New Potential Therapeutic Targets in Autoimmune Diseases
Current Pharmaceutical Design Therapeutic Interventions to Renin-Angiotensin-Aldosterone System, and Vascular Redox State
Recent Patents on Cardiovascular Drug Discovery Cytokine Polymorphisms in Chronic Inflammatory Diseases with Reference to Occupational Diseases
Current Molecular Medicine Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Dendritic Cells in Hepatitis Virus Infection: A Legatus Within
Current Immunology Reviews (Discontinued) Hereditary Papillary Renal Carcinoma Type I
Current Molecular Medicine Silymarin as a New Hepatoprotective Agent in Experimental Cholestasis: New Possibilities for an Ancient Medication
Current Medicinal Chemistry Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology Therapeutic Targeting of Endothelial Dysfunction in Chronic Diabetic Complications
Recent Patents on Cardiovascular Drug Discovery MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases
Current Immunology Reviews (Discontinued) Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
Cardiovascular & Hematological Agents in Medicinal Chemistry DNA Copy Number Profiles Correlate with Outcome in Colorectal Cancer Patients Treated with Fluoropyrimidine/Antifolate-based Regimens
Current Drug Metabolism Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design